

RECEIVED
CENTRAL FAX CENTER

MAR 17 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**OFFICIAL**

Application No.: 10/019,890
Filing Date: June 5, 2002
First Named Inventor: Curry
Title: 2-Aminoindane Analogs
Attorney Docket No.: MBMCO P-1
Examiner: Zucker
Art Unit: 1621

#8/B
4/8/4
F. MeierVia RightFax (Before Final): 703-872-9306 (19 pg. incl. cover)

Commissioner for Patents
P.O. Box 1450
Washington, DC 22313-1450

FACSIMILE TRANSMITTAL

Honorable Sir:

Transmitted herewith is an Election of Species and Amendment for the above-identified application.

CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being transmitted to the attention of Paul Zucker of Art Unit 2621 at Facsimile Number 703 872 9306 on March 17, 2004 in accordance with 37 CFR 1.6(d).

March 17, 2004
Date


Thomas Blankinship

09/24/2004 EEKUBAY1 00000001 100100 10019830

01 FC:2255 1005.00 DA

04/21/2004 FMEGER 00000006 100100 10019830
01 FC:1255 2010.00 DA
Adjustment date: 09/24/2004 EEKUBAY1 10019830
04/21/2004 FMEGER 00000006 100100 10019830
01 FC:1255 2010.00 CR

RECEIVED
CENTRAL FAX CENTER

MAR 17 2004

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/019,890
Filing Date: June 5, 2002
First Named Inventor: Curry
Title: 2-Aminoindane Analogs
Attorney Docket No.: MBMCO P-1
Examiner: Zucker
Art Unit: 1621

Via RightFax (Before Final): 703-872-9306 (19 pg. incl. cover)

Commissioner for Patents
P.O. Box 1450
Washington, DC 22313-1450

ELECTION OF SPECIES AND AMENDMENT

Honorable Sir:

This is an Election of Species and Amendment for the above-identified application in response to the Office Action mail September 17, 2003. The Applicant hereby respectfully requests an Extension of three (3) months in which to response to the Office Action. The Commissioner is hereby authorized to charge the 3-month extension fee to Deposit Account No. 10-0100 for Lackenbach Siegel, LLP.

ELECTION OF SPECIES

Applicant hereby elects compound 8 as shown on page 38 and claimed in its isomeric forms in dependent claims 4, 7, and 11, namely the top two structures of those claims. Independent claim 1 recites a generic formula (I) that includes compound 8. Independent claim 5 relates to the process for the preparation of a compound of generic formula (I) encompassing the elected compound 8 within its scope. Claims 12 to 17 relate to the intermediates formed in the process of preparing the compound of generic formula (I) as claimed in claim 5.